| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
(ISIS 3521/CGP 64128A1 ) in Patients with Cancer,2
Oncology Division, Stanford University School of Medicine, Stanford, California 94305 [A. R. Y., J. H., G. A. F., B. I. S.], and Isis Pharmaceuticals, Inc., Carlsbad, California 92008 [J. T. H., R. S. G., T. J. K., A. D.]
Protein kinase C (PKC) is an attractive target in cancer therapy. It is overexpressed in a variety of cancers, and nonspecific inhibitors of PKC have demonstrated antitumor activity. Antisense oligonucleotides targeted against PKC-
, which have high specificity, can inhibit mRNA and protein expression as well as the growth of tumors in vitro and in vivo. This Phase I study sought to characterize the safety profile and to determine the maximum tolerated dose of antisense to PKC- when administered by continuous infusion in patients. Patients with incurable malignancies received ISIS 3521, a 20-length phosphorothioate oligodeoxynucleotide specific for PKC-. Treatment was delivered over a period of 21 days by continuous i.v. infusion followed by a 7-day rest period. Doses were increased from 0.5 to 3.0 mg/kg/day. Patients continued on the study until evidence of disease progression or unacceptable toxicity was detected. Between August 1996 and September 1997, 21 patients were treated in five patient cohorts. The maximum tolerated dose was 2.0 mg/kg/day. The dose-limiting toxicities were thrombocytopenia and fatigue at a dose of 3.0 mg/kg/day. Pharmacokinetic measurements showed rapid plasma clearance and dose-dependent steady-state concentrations of ISIS 3521. Evidence of tumor response lasting up to 11 months was observed in three of four patients with ovarian cancer. The recommended dose of ISIS 3521 for Phase II studies is 2.0 mg/kg/day when given over a period of 21 days. Side effects are modest and consist of thrombocytopenia and fatigue. Evidence of antitumor activity provides the rationale for Phase II studies in ovarian cancer and other malignancies.
This article has been cited by other articles:
|
|
 |
|
  G. Liu, J. Kolesar, D. G. McNeel, C. Leith, K. Schell, J. Eickhoff, F. Lee, A. Traynor, R. Marnocha, D. Alberti, et al. A Phase I Pharmacokinetic and Pharmacodynamic Correlative Study of the Antisense Bcl-2 Oligonucleotide G3139, in Combination with Carboplatin and Paclitaxel, in Patients with Advanced Solid Tumors Clin. Cancer Res., May 1, 2008; 14(9): 2732 - 2739. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Thomas, M. J. Ogagan, M. L. Freilino, S. Strychor, D. R. Walsh, W. E. Gooding, J. R. Grandis, and W. C. Zamboni Antitumor Mechanisms of Systemically Administered Epidermal Growth Factor Receptor Antisense Oligonucleotides in Combination with Docetaxel in Squamous Cell Carcinoma of the Head and Neck Mol. Pharmacol., March 1, 2008; 73(3): 627 - 638. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Guergnon, F. Dessauge, V. Dominguez, J. Viallet, S. Bonnefoy, V. J. Yuste, O. Mercereau-Puijalon, X. Cayla, A. Rebollo, S. A. Susin, et al. Use of Penetrating Peptides Interacting with PP1/PP2A Proteins As a General Approach for a Drug Phosphatase Technology Mol. Pharmacol., April 1, 2006; 69(4): 1115 - 1124. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Paz-Ares, J.-Y. Douillard, P. Koralewski, C. Manegold, E. F. Smit, J. M. Reyes, G.-C. Chang, W. J. John, P. M. Peterson, C. K. Obasaju, et al. Phase III Study of Gemcitabine and Cisplatin With or Without Aprinocarsen, a Protein Kinase C-Alpha Antisense Oligonucleotide, in Patients With Advanced-Stage Non-Small-Cell Lung Cancer J. Clin. Oncol., March 20, 2006; 24(9): 1428 - 1434. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Springett, L. Bonham, A. Hummer, I. Linkov, D. Misra, C. Ma, G. Pezzoni, S. Di Giovine, J. Singer, H. Kawasaki, et al. Lysophosphatidic Acid Acyltransferase-{beta} Is a Prognostic Marker and Therapeutic Target in Gynecologic Malignancies Cancer Res., October 15, 2005; 65(20): 9415 - 9425. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Jelacic and D. Linnekin PKC{delta} plays opposite roles in growth mediated by wild-type Kit and an oncogenic Kit mutant Blood, March 1, 2005; 105(5): 1923 - 1929. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Grossman, J. B. Alavi, J. G. Supko, K. A. Carson, R. Priet, F. A. Dorr, J. S. Grundy, and J. T. Holmlund Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-{alpha} delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas Neuro-oncol, January 1, 2005; 7(1): 32 - 40. [Abstract] [PDF]
|
|
|
|
|
|
M. A. Villalona-Calero, P. Ritch, J. A. Figueroa, G. A. Otterson, R. Belt, E. Dow, S. George, J. Leonardo, S. McCachren, G. L. Miller, et al. A Phase I/II Study of LY900003, an Antisense Inhibitor of Protein Kinase C-{alpha}, in Combination with Cisplatin and Gemcitabine in Patients with Advanced Non-Small Cell Lung Cancer Clin. Cancer Res., September 15, 2004; 10(18): 6086 - 6093. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Rao, D. Watkins, D. Cunningham, D. Dunlop, P. Johnson, P. Selby, B. W. Hancock, C. Fegan, D. Culligan, S. Schey, et al. Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkin's lymphoma Ann. Onc., September 1, 2004; 15(9): 1413 - 1418. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Marshall, H. Chen, D. Yang, M. Figueira, K. B. Bouker, Y. Ling, M. Lippman, S. R. Frankel, and D. F. Hayes A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors Ann. Onc., August 1, 2004; 15(8): 1274 - 1283. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. R. Parulekar and E. A. Eisenhauer Phase I Trial Design for Solid Tumor Studies of Targeted, Non-Cytotoxic Agents: Theory and Practice J Natl Cancer Inst, July 7, 2004; 96(13): 990 - 997. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Monnerat, R. Henriksson, T. Le Chevalier, S. Novello, P. Berthaud, S. Faivre, and E. Raymond Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer Ann. Onc., February 1, 2004; 15(2): 316 - 323. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Burkhart, A. J. Cheng, J. Madafiglio, M. Kavallaris, M. Mili, G. M. Marshall, W. A. Weiss, L. M. Khachigian, M. D. Norris, and M. Haber Effects of MYCN Antisense Oligonucleotide Administration on Tumorigenesis in a Murine Model of Neuroblastoma J Natl Cancer Inst, September 17, 2003; 95(18): 1394 - 1403. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Fluiter, A. L. M. A. ten Asbroek, M. B. de Wissel, M. E. Jakobs, M. Wissenbach, H. Olsson, O. Olsen, H. Oerum, and F. Baas In vivo tumor growth inhibition and biodistribution studies of locked nucleic acid (LNA) antisense oligonucleotides Nucleic Acids Res., February 1, 2003; 31(3): 953 - 962. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. W. Tolcher, L. Reyno, P. M. Venner, S. D. Ernst, M. Moore, R. S. Geary, K. Chi, S. Hall, W. Walsh, A. Dorr, et al. A Randomized Phase II and Pharmacokinetic Study of the Antisense Oligonucleotides ISIS 3521 and ISIS 5132 in Patients with Hormone-refractory Prostate Cancer Clin. Cancer Res., August 1, 2002; 8(8): 2530 - 2535. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Cripps, A. T. Figueredo, A. M. Oza, M. J. Taylor, A. L. Fields, J. T. Holmlund, L. W. McIntosh, R. S. Geary, and E. A. Eisenhauer Phase II Randomized Study of ISIS 3521 and ISIS 5132 in Patients with Locally Advanced or Metastatic Colorectal Cancer: A National Cancer Institute of Canada Clinical Trials Group Study Clin. Cancer Res., July 1, 2002; 8(7): 2188 - 2192. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Mani, C. M. Rudin, K. Kunkel, J. T. Holmlund, R. S. Geary, H. L. Kindler, F. A. Dorr, and M. J. Ratain Phase I Clinical and Pharmacokinetic Study of Protein Kinase C-{alpha} Antisense Oligonucleotide ISIS 3521 Administered in Combination with 5-Fluorouracil and Leucovorin in Patients with Advanced Cancer Clin. Cancer Res., April 1, 2002; 8(4): 1042 - 1048. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Wang, M. Nomura, S. Patan, and J. A. Ware Inhibition of Protein Kinase C{alpha} Prevents Endothelial Cell Migration and Vascular Tube Formation In Vitro and Myocardial Neovascularization In Vivo Circ. Res., March 22, 2002; 90(5): 609 - 616. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Morris, W. P. Tong, C. Cordon-Cardo, M. Drobnjak, W. K. Kelly, S. F. Slovin, K. L. Terry, K. Siedlecki, P. Swanson, M. Rafi, et al. Phase I Trial of BCL-2 Antisense Oligonucleotide (G3139) Administered by Continuous Intravenous Infusion in Patients with Advanced Cancer Clin. Cancer Res., March 1, 2002; 8(3): 679 - 683. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. B. da Rocha, D.R.A. Mans, A. Regner, and G. Schwartsmann Targeting Protein Kinase C: New Therapeutic Opportunities Against High-Grade Malignant Gliomas? Oncologist, February 1, 2002; 7(1): 17 - 33. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Benimetskaya, P. Miller, S. Benimetsky, A. Maciaszek, P. Guga, S. L. Beaucage, A. Wilk, A. Grajkowski, A. L. Halperin, and C. A. Stein Inhibition of Potentially Anti-Apoptotic Proteins by Antisense Protein Kinase C-alpha (Isis 3521) and Antisense bcl-2 (G3139) Phosphorothioate Oligodeoxynucleotides: Relationship to the Decreased Viability of T24 Bladder and PC3 Prostate Cancer Cells Mol. Pharmacol., December 1, 2001; 60(6): 1296 - 1307. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Geary, T. A. Watanabe, L. Truong, S. Freier, E. A. Lesnik, N. B. Sioufi, H. Sasmor, M. Manoharan, and A. A. Levin Pharmacokinetic Properties of 2'-O-(2-Methoxyethyl)-Modified Oligonucleotide Analogs in Rats J. Pharmacol. Exp. Ther., March 1, 2001; 296(3): 890 - 897. [Abstract] [Full Text]
|
|
|
|
|
|
P. Rojnuckarin and K. Kaushansky Actin reorganization and proplatelet formation in murine megakaryocytes: the role of protein kinase C{alpha} Blood, January 1, 2001; 97(1): 154 - 161. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. R. Khuri and J. M. Kurie Antisense Approaches Enter the Clinic Clin. Cancer Res., May 1, 2000; 6(5): 1607 - 1610. [Full Text]
|
|
|
|
|
|
A. Wang, M. Nomura, S. Patan, and J. A. Ware Inhibition of Protein Kinase C{alpha} Prevents Endothelial Cell Migration and Vascular Tube Formation In Vitro and Myocardial Neovascularization In Vivo Circ. Res., March 22, 2002; 90(5): 609 - 616. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
